Video
Dr. Jonasch on HIF-2α inhibitors in renal cell carcinoma
Author(s):
Video Player is loading.
Eric Jonasch, MD, discusses the potential of HIF-2α inhibitors, an emerging class of agents for the treatment of patients with renal cell carcinoma. Jonasch is a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer
Paul Sieber, MD, on the future of genetic testing in prostate cancer
Daniel Kwon, MD, discusses study’s impact on veteran access to germline testing for prostate cancer
Tim Richardson, MD, on genetic testing in the era of targeted therapies
Discussing germline testing for prostate cancer with veterans
Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing
Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer
Germline testing study’s implications for veteran access to prostate cancer treatments
Kara Cossis, PA-C, MPH, on challenges, opportunities with genetic testing
Daniel Kwon, MD, on germline testing for prostate cancer in veterans with service-connected benefits
Related Content
